CN109091636B - Zhuang medicine formula for treating coronary heart disease and preparation method thereof - Google Patents
Zhuang medicine formula for treating coronary heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN109091636B CN109091636B CN201811278200.8A CN201811278200A CN109091636B CN 109091636 B CN109091636 B CN 109091636B CN 201811278200 A CN201811278200 A CN 201811278200A CN 109091636 B CN109091636 B CN 109091636B
- Authority
- CN
- China
- Prior art keywords
- parts
- heart disease
- coronary heart
- treating coronary
- zhuang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a Zhuang nationality medicine formula for treating coronary heart disease and a preparation method thereof. The Zhuang nationality medicine formula is prepared from the following raw material components: caulis Seu folium Euonymi Fortunei, caulis Spatholobi, herba Cymbopogonis Citrari, radix Cynanchi Paniculati, Notoginseng radix, radix Polygalae Fallacis, herba Gynostemmatis, radix Achyranthis, radix Acanthopanacis Senticosi, herba Centipedae, Coicis semen, and caulis Sargentodoxae. The Zhuang nationality medicine formula for treating coronary heart disease is elaborately developed according to the traditional Chinese medicine formula and the preparation principle, and the effective components are extracted according to the modern extraction technology of traditional Chinese medicines, so that the Zhuang nationality medicine has the characteristics of strong pertinence, good curative effect and no toxic or side effect.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the field of traditional Chinese medicines, and in particular relates to a Zhuang nationality medicine formula for treating coronary heart disease and a preparation method thereof.
[ background of the invention ]
Coronary heart disease is called coronary heart disease for short, and the coronary heart disease causes myocardial ischemia due to the change of hemodynamics caused by the pathological changes of blood vessels, is easy to cause acute myocardial infarction and seriously harms the life of a patient.
The treatment of coronary heart disease mainly comprises interventional therapy and drug therapy at present. The short-term effect of interventional therapy is obvious, but the incidence rate of adverse cardiac events and cardiovascular events after treatment is high, and the long-term effect is not ideal; in the medical treatment, the recent treatment using the minority nationality medicine has certain advantages. In Zhuang medical theory, coronary heart disease belongs to the disease of Longlu, the Longlu is equivalent to the blood vessel of human body, and the disease of Longlu is a disease of the obstructed Longlu, unsmooth blood circulation or the function of the Longlu is lost, the blood circulation does not follow the normal path and the orifice produces blood. Zhuang medicine is based on Zhuang medicine theory and starts from the angle of dredging the dragon road of human body, and the medicine with the function of dredging the dragon road is applied to achieve the effect, and the raw materials of the medicine are easy to obtain, and the treatment effect is proved by practice.
At present, the prescription of the medicine for coronary heart disease focuses on short-term effect partially, and ignores long-term curative effect to a certain extent; in addition, some of the formulas contain various rare medicines, so that the medicine cost is higher; the bioavailability of the components in part of the formula is not high and the components are difficult to absorb; and the processing and preparing process of the components in the formula is complicated, time-consuming and labor-consuming, and causes certain difficulty in popularization and application.
Therefore, aiming at the treatment of coronary heart disease, a formula with the advantages of low cost, easy absorption, simple processing and easy popularization should be developed, thereby obtaining better effects on the short-term curative effect and the long-term curative effect of coronary heart disease.
[ summary of the invention ]
The invention aims to: aiming at the defects of the prior art, the Zhuang nationality medicine formula for treating coronary heart disease and the preparation method thereof are provided, the Zhuang nationality medicine formula for treating coronary heart disease is elaborately developed according to the traditional Chinese medicine formula and the preparation principle, the effective components are extracted according to the modern extraction technology of traditional Chinese medicines, and the Zhuang nationality medicine formula has the characteristics of strong pertinence, good curative effect and no toxic or side effect.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the Zhuang nationality medicine formula for treating coronary heart disease is prepared from the following raw material components: caulis Seu folium Euonymi Fortunei, caulis Spatholobi, herba Cymbopogonis Citrari, radix Cynanchi Paniculati, Notoginseng radix, radix Polygalae Fallacis, herba Gynostemmatis, radix Achyranthis, radix Acanthopanacis Senticosi, herba Centipedae, Coicis semen, and caulis Sargentodoxae.
Further, the feed additive is prepared from the following raw material components: 10-12 parts of euonymus fortunei, 10-12 parts of caulis spatholobi, 8-10 parts of citronella, 6-8 parts of cynanchum paniculatum, 6-8 parts of pseudo-ginseng, 4-6 parts of polygala fallax hemsl, 3-5 parts of gynostemma pentaphylla, 8-10 parts of achyranthes aspera, 10-12 parts of acanthopanax, 10-12 parts of centipeda minima, 8-10 parts of coix seed and 1-3 parts of sargentgloryvine stem.
Preferably, the compound is prepared from the following raw material components: 11 parts of euonymus fortunei, 11 parts of caulis spatholobi, 9 parts of citronella, 7 parts of paniculate swallowwort root, 7 parts of pseudo-ginseng, 5 parts of polygala fallax hemsl, 4 parts of gynostemma pentaphylla, 9 parts of achyranthes aspera, 11 parts of acanthopanax, 11 parts of centipeda minima, 9 parts of coix seed and 2 parts of sargentgloryvine stem.
The preparation method of the Zhuang nationality medicine formula for treating coronary heart disease comprises the following steps: weighing the raw material components according to the proportion, drying, crushing into fine powder, sieving and mixing uniformly to obtain the composition.
The preparation method of the Zhuang nationality medicine formula for treating coronary heart disease comprises the following steps: weighing the raw material components according to the proportion, crushing the raw material components into medicinal coarse powder, and decocting the medicinal coarse powder for 1-3 times with 6-12 times of water at 90-100 ℃ for 1-3 hours each time; mixing the medicinal liquids, and filtering; concentrating the filtrate to obtain extract; or further drying the extract, and pulverizing into dry extract powder.
Further, the preparation method of the Zhuang nationality medicine formula for treating coronary heart disease comprises the following steps: weighing the raw material components according to the proportion, and crushing the raw material components into medicinal coarse powder; adding 6-12 times of water into the crude powder of the medicinal materials, uniformly mixing to obtain a suspension, soaking for 30min, decocting for 2 times at 90-100 ℃ for 2h each time, combining liquid medicines, filtering, concentrating the filtrate, drying in vacuum at 70-80 ℃, and crushing the obtained dry extract to obtain dry extract powder.
In the dry extract powder, the mass percentage content of the total flavone is more than or equal to 17.6 percent.
A Zhuang medicine preparation for treating coronary heart disease comprises an effective amount of the Zhuang medicine formula or the Zhuang medicine formula prepared by the method and a pharmaceutically acceptable carrier.
In the embodiment of the invention, the content of the total flavone is determined as follows: measured according to the SN/T4592-2016 standard.
The drug effects of the medicines in the formula are as follows:
wintercreeper: the record of the Chinese Zhuang medicine: "unblock Longlu, Huoluo, relax muscles and tendons, stop bleeding, dissipate blood stasis"; has the effects of promoting blood circulation and removing blood stasis.
Caulis spatholobi: mild in nature, slightly bitter, sweet and astringent; promoting blood circulation, tonifying blood, dredging meridian passage. Can be used for treating anemia, menoxenia, rheumatic arthralgia, numbness of limbs, and arthralgia.
Citronella: pungent and warm; dispel wind and dampness, relieve swelling and pain, and dredge the meridians and fire paths. Can be used for treating rheumatalgia, headache, gastralgia, diarrhea, menoxenia, puerperal edema, and traumatic injury with swelling and pain.
Paniculate swallowwort root: pungent and warm taste; tranquilizing and relieving pain. Can improve myocardial metabolism, and relieve myocardial ischemia.
Pseudo-ginseng: sweet, slightly bitter and warm; the record of the Chinese Zhuang medicine: the Chinese medicinal composition has the effects of tonifying deficiency, strengthening body constitution, eliminating dampness, removing toxic substances, removing blood stasis, stopping bleeding, and relieving swelling and pain.
Radix Polygalae Fallacis: mild in nature, sweet and slightly bitter in taste; has the functions of invigorating qi and blood, dispelling wind-damp and strengthening bones and muscles. Can be used for treating weakness after illness, soreness of waist and knees, and asthenia of heart.
Gynostemma pentaphylla: mild in nature and slightly bitter; promoting blood circulation, tonifying blood, dredging meridian passage, and regulating LONGLUO.
Achyranthes aspera: sweet, light and cool; promoting blood circulation, dispelling blood stasis, dredging channels, and promoting urination. Can be used for treating rheumatalgia, heart deficiency, and debilitation.
Acanthopanax root, radix acanthopanacis senticosi, sweet in nature and slightly bitter; it can be used for treating short breath, asthenia, palpitation, asthenia, and listlessness.
Centipeda minima: pungent and warm; dispelling pathogenic wind, promoting blood circulation, and inducing resuscitation. It can be used for treating short breath, asthenia, palpitation, and severe palpitation.
Coix seed: sweet, light and slightly cool; induce diuresis to alleviate edema, invigorate spleen to remove dampness, relax muscles and tendons to remove arthralgia, clear heat and expel pus. It is indicated for arthralgia due to wind-dampness, flaccidity of limbs, soreness and pain of waist and back, edema, dyspnea, pulmonary abscess, cough and saliva, and heat stranguria due to sand and stone.
Sargentgloryvine stem: bitter and flat; clearing away heat and toxic material, promoting blood circulation and dispelling pathogenic wind. Can be used for treating rheumatalgia, traumatic injury, swelling and pain, appendicitis, abdominal pain, amenorrhea, and dysmenorrhea.
In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that:
(1) caulis Seu folium Euonymi Fortunei has effects of tranquilizing, relieving convulsion, resisting inflammation, relieving pain, and reducing myocardial fatigue; caulis Spatholobi has effects in increasing coronary blood flow and myocardial nutrition blood flow for cardiovascular system; the herba Cymbopogonis Citrari and herba Gynostemmatis have effects of tonifying heart, dilating blood vessel, increasing blood flow, and promoting blood circulation; the Polygala fallax Hemsl has direct relaxation effect on gastrointestinal smooth muscle, has prevention effect on tissue injury, and has effects of tranquilizing and immunoregulation; notoginseng radix and radix Acanthopanacis Senticosi have hemostatic effect, and also have effects of inhibiting platelet function and promoting fibrinolysis, reducing oxygen consumption of myocardium and resisting arrhythmia; the radix Achyranthis has effects of improving myocardial contraction force and cardiac output, resisting shock, dilating blood vessel, regulating gastrointestinal dysfunction, and promoting absorption; coicis semen has effects of stabilizing myocardial cell membrane, regulating immunity, resisting inflammation, and tranquilizing mind; caulis Sargentodoxae has effects in improving myocardial contraction force, dilating coronary artery, protecting myocardial cell, improving cardiac function, relieving heart circulatory disturbance caused by acute myocardial infarction, promoting coronary artery dilation or collateral blood vessel opening, and protecting heart;
the euonymus fortunei, the caulis spatholobi and the citronella are combined to synergistically increase coronary blood flow and cardiac muscle nutrition blood flow so as to promote blood circulation; the gynostemma pentaphylla, the pseudo-ginseng and the acanthopanax are combined to synergistically enhance myocardial contractility, increase cardiac output and expand blood vessels, and the coix seed, the centipeda minima and the sargentgloryvine stem are combined to stabilize myocardial cell membranes, resist inflammation, calm and protect the heart. The medicinal and flavor composition in the formula can expand coronary artery, increase myocardial nutrition and blood volume, improve heart function, and also can maintain normal shape and blood fluidity of blood vessel by improving gastrointestinal function and absorbing and dissipating blood stasis blocking blood vessel by human tissue. The combination of the medicines embodies the characteristic of dredging the dragon road of a human body to treat the dragon road disease in terms of treatment by the theory of sound medical science;
the raw materials in the formula are commonly used and are easy to obtain, the cost is low, and the processing is simple. Can be processed into different preparations according to the disease condition of patients, such as pills, decoctions or granules, and is easy to take; meanwhile, aiming at the coronary heart disease, the traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis and protecting cardiac vessels, is mild and durable in medicine property, has no side effect, is suitable for long-term administration, and considers the short-term curative effect and the long-term curative effect on the treatment of the coronary heart disease.
(2) Animal experiments prove that the formula of the invention has obvious curative effect on coronary heart disease and no toxic or side effect.
[ description of the drawings ]
FIG. 1 is a graph showing morphological changes of myocardium in each group in example 6 of the present invention.
[ detailed description ] embodiments
Example 1
Prescription (parts by weight): 11 parts of euonymus fortunei, 11 parts of caulis spatholobi, 9 parts of citronella, 7 parts of paniculate swallowwort root, 7 parts of pseudo-ginseng, 5 parts of polygala fallax hemsl, 4 parts of gynostemma pentaphylla, 9 parts of achyranthes aspera, 11 parts of acanthopanax, 11 parts of centipeda minima, 9 parts of coix seed and 2 parts of sargentgloryvine stem.
The preparation method comprises the following steps: crushing the twelve medicines into medicinal material coarse powder; adding 6 times of water into the crude powder of the medicinal materials, uniformly mixing to obtain a suspension, soaking for 30min, decocting for 2 times at 90-100 ℃ for 2h each time, combining liquid medicines, filtering, concentrating the filtrate, drying in vacuum at 70-80 ℃ until the water content is less than or equal to 5%, and crushing the obtained dry extract to obtain dry extract powder.
In the dry extract powder described in this example, the content of total flavonoids is 17.6% by mass.
Example 2
Prescription (parts by weight): 11 parts of euonymus fortunei, 11 parts of caulis spatholobi, 9 parts of citronella, 7 parts of paniculate swallowwort root, 7 parts of pseudo-ginseng, 5 parts of polygala fallax hemsl, 4 parts of gynostemma pentaphylla, 9 parts of achyranthes aspera, 11 parts of acanthopanax, 11 parts of centipeda minima, 9 parts of coix seed and 2 parts of sargentgloryvine stem.
The preparation method comprises the following steps: crushing the twelve medicines into medicinal material coarse powder (sieving by a 20-mesh sieve); decocting the crude medicinal powder for 1 time at 90-100 ℃ by using 12 times of water by weight, wherein the decocting time is 3 hours; filtering, concentrating the filtrate, vacuum drying at 70-80 deg.C until the water content is less than or equal to 5%, and pulverizing the obtained dry extract to obtain dry extract powder.
In the dry extract powder described in this example, the content of total flavonoids is 18.2% by mass.
Example 3
Prescription (parts by weight): 11 parts of euonymus fortunei, 11 parts of caulis spatholobi, 9 parts of citronella, 7 parts of paniculate swallowwort root, 7 parts of pseudo-ginseng, 5 parts of polygala fallax hemsl, 4 parts of gynostemma pentaphylla, 9 parts of achyranthes aspera, 11 parts of acanthopanax, 11 parts of centipeda minima, 9 parts of coix seed and 2 parts of sargentgloryvine stem.
The preparation method comprises the following steps: the twelve medicines are prepared into pills by firstly obtaining dry extract powder according to the preparation method of the example 1 and then adding auxiliary materials.
Example 4
Prescription (parts by weight): 10 parts of euonymus fortunei, 10 parts of caulis spatholobi, 8 parts of citronella, 6 parts of paniculate swallowwort root, 6 parts of pseudo-ginseng, 4 parts of polygala fallax hemsl, 3 parts of gynostemma pentaphylla, 8 parts of achyranthes aspera, 10 parts of acanthopanax, 10 parts of centipeda minima, 8 parts of coix seed and 1 part of sargentgloryvine stem.
The preparation method comprises the following steps: the twelve medicines are prepared into capsules by firstly obtaining dry extract powder according to the preparation method of the embodiment 2 and then adding auxiliary materials.
Example 5
Prescription (parts by weight): 12 parts of euonymus fortunei, 12 parts of caulis spatholobi, 10 parts of citronella, 8 parts of paniculate swallowwort root, 8 parts of pseudo-ginseng, 6 parts of polygala fallax hemsl, 5 parts of gynostemma pentaphylla, 10 parts of achyranthes aspera, 12 parts of acanthopanax, 12 parts of centipeda minima, 10 parts of coix seed and 3 parts of sargentgloryvine stem.
The preparation method comprises the following steps: the twelve medicines are prepared into granules by firstly obtaining dry extract powder according to the preparation method of the embodiment 2 and then adding auxiliary materials.
To demonstrate the therapeutic effect of the Zhuang nationality drug formulation of the present invention, the applicant conducted the following toxicological and pharmacodynamic experiments.
EXAMPLE 6 toxicological, pharmacodynamic and clinical treatment typical cases of Zhuang medicine formulation of the present invention
1. Toxicology test of animals
(1) Acute poisoning test for animals
Test animals: SPF-grade BALB/c mice were 100, half male and half female, and weighed (22. + -.2) g.
The test method comprises the following steps: the formula pill (prepared in example 3) is added with a proper amount of double distilled water and stirred uniformly, the mixture is heated in a water bath to prepare a Zhuang medicine liquid with the concentration of 20%, the stomach of a mouse is irrigated according to the weight of 20g/kg, the tolerance of the stomach is 100 times of that of a clinical patient, the mouse has slight activity enhancement after administration for 35 minutes, the mouse recovers to be normal after about 1 hour, behavioral observation is carried out on the mouse for 7 days continuously, and the mouse has normal activity, diet, water intake, defecation and weight increase. The results of the mouse gavage administration acute poisoning test show that the formula is safe to administer through the digestive tract.
(2) Long term toxicity test in animals
Test animals: SPF grade Wistar rats 90 with half male and female body weight (170. + -. 12) g.
The test method comprises the following steps: the rats are divided into 3 groups, namely a formula gavage administration low dose group (short for a low dose group), a formula gavage administration medium dose group (short for a medium dose group) and a formula gavage administration high dose group (short for a high dose group), and each group contains 30 rats. The formula pill (prepared in example 3) is added with a proper amount of double distilled water and stirred uniformly, the mixture is heated in a water bath to prepare Zhuang medicine liquid with the concentration of 20 percent, and the unit weight intragastric administration dosage of the low dose group, the medium dose group and the high dose group is respectively equal to 0.5, 2 and 5 times of the equivalent dosage of clinical patients. Continuously performing gavage administration for 180 days, performing behavioral observation of rats, killing the rats after gavage, and performing blood biochemical detection by using the sacrificed rats, wherein the detection indexes comprise alanine Aminotransferase (ALT) activity, aspartate Aminotransferase (AST) activity, serum creatinine (SCr), serum urea nitrogen (BUN) and urine creatinine (UCr) indexes reflecting liver and kidney functions; meanwhile, taking HE staining of liver and kidney tissues for morphological observation. In addition, 30 rats were used as normal control groups (referred to as control groups for short), and the blood biochemical detection and morphological observation were performed in the same manner for each dose group after sacrifice. The results show that the rats were active normally during the gavage period, as well as diet, water intake, stool and urine, and weight gain. The detection results of various indexes of blood biochemistry and the observation results of pathological morphology show that compared with a control group, no abnormity or pathological changes appear in each dosage group.
2. Pharmacodynamic test of animals
Test animals: SPF grade SD rats 150 with half male and female body weight (165 + -15) g.
The test method comprises the following steps: the rats are divided into 5 groups, namely a normal control group (a control group for short), a coronary heart disease animal model group (a model group for short), a formula gastric perfusion administration low-dose group (a low-dose group for short), a formula gastric perfusion administration medium-dose group (a medium-dose group for short) and a formula gastric perfusion administration high-dose group (a high-dose group for short), and each group contains 30 rats. The model group, the low dose group, the medium dose group and the high dose group are all used for coronary heart disease modeling. The molding method comprises the following steps: 3.5mL/kg of 10% chloral hydrate is injected into an abdominal cavity of a rat for anesthesia, mechanical ventilation and electrocardiographic monitoring are carried out, a chest is opened on the left side, the heart is exposed, and the anterior descending branch of the left coronary artery is ligated to prepare an animal model of the coronary heart disease. After molding, the formulation pill (prepared in example 3) is added with a proper amount of double distilled water and stirred uniformly, and is heated in a water bath to prepare a Zhuang nationality medicine liquid with the concentration of 20%, and the unit weight intragastric administration dosage of the low dose group, the medium dose group and the high dose group is respectively equal to 0.5, 2 and 5 times of the equivalent dosage of a clinical patient. The control group and the model group were subjected to intragastric gavage with physiological saline of equal volume. Each group was administered by continuous gavage for 4 weeks. The rats are sacrificed 2 hours after the last intragastric administration to take materials and detect the activities of myocardial Creatine Kinase (CK) and Lactate Dehydrogenase (LDH), and the morphological change of myocardial tissues is observed by HE staining.
③ the test result: statistical analysis shows that the CK activity and the LDH activity of each dosage group are improved to different degrees, the levels of the dosage groups are close to the levels of a control group, and the differences have statistical significance compared with a model group; morphological observation results show that the myocardium of the control group is uniformly dyed, the myocardium structure is complete and clear, and transverse striations are regularly arranged; the staining of the model group is light, the arrangement of the myocardial fibers is disordered, the gaps are widened, and partial cells are dissolved, necrotic and disappear; the myocardial fiber arrangement, the cytolytic necrosis condition and the model group comparison of each dose group are improved to different degrees. The experimental results show that the formula has different degrees of improvement effects on myocardial tissues of coronary heart disease and myocardial metabolism after intragastric administration. Experimental results table 1 and fig. 1.
TABLE 1 comparison of CK, LDH levels in groups
Note: compared with the control group, the compound of the formula,ΔP<0.05; in comparison with the set of models,*P<0.05。
3. typical case of clinical treatment
(1) Wenzhi, male, age 52. The patients with chest distress, palpitation and hypodynamia repeatedly attack for 3 years, and the patients with the symptoms aggravated for 1 week are diagnosed in 2015 for 6 months. The patient is hospitalized for chest distress and chest pain before 3 years and is systematically examined, the patient is diagnosed as coronary heart disease, the symptoms of chest distress and chest pain after coronary artery dilatation and cardiac muscle nutrition and cardiac blood circulation improvement are relieved, but the symptoms of chest distress and palpitation after fatigue or qi generation are aggravated after the treatment of the later half year, and the symptoms of chest distress, chest pain and palpitation accompanied by hyperhidrosis insomnia, anorexia and fatigue and hypodynamia are aggravated, so the patient is helped to be treated by strong doctors. 6 pills (6 g per pill) are taken in the morning and evening for 2 times every day, 3 pills are taken with warm boiled water each time, 1 treatment course is 7 days, 4 treatment courses are continuously taken, chest distress, chest pain and palpitation symptoms disappear, appetite is increased, conscious steps of going upstairs and downstairs are powerful, the electrocardiogram is basically normal after reexamination, the general condition is improved, and no relapse occurs in 1 year of follow-up visit.
(2) Lie, woman, 56 years old. The patients with chest distress and chest pain can be diagnosed in 2016 and 10 months. Chest pain, chest distress and palpitation begin to appear before 6 months, but the symptoms are light and unappreciated, chest pain, chest distress and palpitation are aggravated recently and are accompanied by dizziness, hypodynamia, anorexia and asthma when moving, coronary heart disease and angina pectoris are diagnosed in a hospital examination, the symptoms are relieved after coronary artery dilation and cardiac microcirculation improvement treatment by using nitric acid and glycerin in the hospital, but symptoms such as chest pain, chest distress, palpitation and the like appear in the near days, and the patients hope to improve the symptoms after conditioning by using folk medicines with lower cost due to economic reasons. 6 pills (6 g per pill) are taken in the morning and evening 2 times per day, 3 pills are taken with warm boiled water each time, 7 days are 1 treatment course, 4 treatment courses are continuously taken, symptoms are improved after the treatment course is finished, the ischemic ST segment is recovered to be normal through electrocardiographic examination, and no recurrence is seen in half a year through follow-up.
The above description is intended to describe in detail the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the claims of the present invention, and all equivalent changes and modifications made within the technical spirit of the present invention should fall within the scope of the claims of the present invention.
Claims (4)
1. The Zhuang medicine composition for treating coronary heart disease is characterized by comprising the following components in parts by weight: the material is prepared from the following raw materials:
10-12 parts of euonymus fortunei, 10-12 parts of caulis spatholobi, 8-10 parts of citronella, 6-8 parts of cynanchum paniculatum, 6-8 parts of pseudo-ginseng, 4-6 parts of radix polygalae fallax, 3-5 parts of gynostemma pentaphylla, 8-10 parts of achyranthes aspera, 10-12 parts of acanthopanax, 10-12 parts of centipeda minima, 8-10 parts of semen coicis and 1-3 parts of sargentgloryvine stem;
the preparation method of the Zhuang medicine composition for treating coronary heart disease comprises the following steps:
weighing the raw material components according to the proportion, crushing the raw material components into medicinal material coarse powder, and decocting the medicinal material coarse powder for 1 to 3 times with 6 to 12 times of water at 90 to 100 ℃ for 1 to 3 hours each time; mixing the medicinal liquids, and filtering; concentrating the filtrate into extract, drying the extract, and pulverizing into dry extract powder;
in the dry extract powder, the mass percentage content of the total flavone is more than or equal to 17.6 percent.
2. The Zhuang medicine composition for treating coronary heart disease according to claim 1, wherein: the material is prepared from the following raw materials: 11 parts of euonymus fortunei, 11 parts of caulis spatholobi, 9 parts of citronella, 7 parts of paniculate swallowwort root, 7 parts of pseudo-ginseng, 5 parts of polygala fallax hemsl, 4 parts of gynostemma pentaphylla, 9 parts of achyranthes aspera, 11 parts of acanthopanax, 11 parts of centipeda minima, 9 parts of coix seed and 2 parts of sargentgloryvine stem.
3. The Zhuang medicine composition for treating coronary heart disease according to claim 1, wherein: weighing the raw material components according to the proportion, and crushing the raw material components into medicinal coarse powder; adding 6-12 times of water into the crude powder, mixing to obtain suspension, soaking for 30min, decocting at 90-100 deg.C for 2 times, each for 2 hr, mixing the medicinal liquids, filtering, concentrating the filtrate, vacuum drying at 70-80 deg.C, and pulverizing the obtained dry extract to obtain dry extract powder.
4. The Zhuang medicine preparation for treating coronary heart disease is characterized by comprising the following components in parts by weight: is prepared from an effective amount of the Zhuang medicine composition for treating coronary heart disease as defined in any one of claims 1-3 and a pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811278200.8A CN109091636B (en) | 2018-10-30 | 2018-10-30 | Zhuang medicine formula for treating coronary heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811278200.8A CN109091636B (en) | 2018-10-30 | 2018-10-30 | Zhuang medicine formula for treating coronary heart disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109091636A CN109091636A (en) | 2018-12-28 |
| CN109091636B true CN109091636B (en) | 2021-05-28 |
Family
ID=64869764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811278200.8A Active CN109091636B (en) | 2018-10-30 | 2018-10-30 | Zhuang medicine formula for treating coronary heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109091636B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105126034A (en) * | 2015-10-05 | 2015-12-09 | 淄博齐鼎立专利信息咨询有限公司 | Pharmaceutical preparation for treating coronary heart disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697841B (en) * | 2012-06-19 | 2014-04-23 | 浙江永宁药业股份有限公司 | Anti-aging compound preparation of Chinese herbs and production method of anti-aging compound preparation |
| CN105920375A (en) * | 2016-07-06 | 2016-09-07 | 贾庭山 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
| CN106138759A (en) * | 2016-08-29 | 2016-11-23 | 姚新亮 | A kind of pharmaceutical composition preventing and treating cardiovascular and cerebrovascular disease |
-
2018
- 2018-10-30 CN CN201811278200.8A patent/CN109091636B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105126034A (en) * | 2015-10-05 | 2015-12-09 | 淄博齐鼎立专利信息咨询有限公司 | Pharmaceutical preparation for treating coronary heart disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109091636A (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078520B (en) | Chinese medicinal preparation for treating nervous headache and preparation method thereof | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN109091636B (en) | Zhuang medicine formula for treating coronary heart disease and preparation method thereof | |
| CN105434738A (en) | Traditional Chinese medicine composition for treating ADHD (Attention Deficit Hyperactivity Disorder) and preparation method thereof | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN104825563B (en) | A kind of Chinese medicine preparation treating cervical spondylosis and preparation method thereof | |
| CN103169838B (en) | Medicine for treating hepatitis B | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN110898195A (en) | Traditional Chinese medicine dietary therapy product for conditioning cerebral apoplexy and preparation method thereof | |
| CN115120657B (en) | Traditional Chinese medicine composition and pharmaceutical preparation for impervious capacity expansion in burn shock period and preparation method | |
| CN109718304A (en) | Improve the Chinese medicine composition of the microcirculation of human body cardio and vascular function and pre- preventing thrombosis | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN100588404C (en) | Chinese traditional medicine compound injection and preparation method thereof | |
| CN106309943A (en) | Coptis chinensis and kudzuvine root capsule and preparation method thereof | |
| Jiang et al. | The pharmacological actions of danshen ThemeD formulas | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN114617939A (en) | Traditional Chinese medicine preparation for treating cerebral arterial thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |